688098 Stock Overview
Engages in the research, development, production, and sale of veterinary biological products in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Shanghai Shen Lian Biomedical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.15 |
| 52 Week High | CN¥8.13 |
| 52 Week Low | CN¥3.80 |
| Beta | 0.64 |
| 11 Month Change | 0.73% |
| 3 Month Change | -24.95% |
| 1 Year Change | -45.11% |
| 33 Year Change | -68.80% |
| 5 Year Change | n/a |
| Change since IPO | -88.73% |
Recent News & Updates
Shareholder Returns
| 688098 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.2% | 0.05% | -1.6% |
| 1Y | -45.1% | -11.8% | -19.6% |
Return vs Industry: 688098 underperformed the CN Pharmaceuticals industry which returned -11.8% over the past year.
Return vs Market: 688098 underperformed the CN Market which returned -19.6% over the past year.
Price Volatility
| 688098 volatility | |
|---|---|
| 688098 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 688098's share price has been volatile over the past 3 months.
Volatility Over Time: 688098's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 380 | Xu Gao | www.slbio.com.cn |
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.
Shanghai Shen Lian Biomedical Corporation Fundamentals Summary
| 688098 fundamental statistics | |
|---|---|
| Market cap | CN¥1.70b |
| Earnings (TTM) | CN¥13.44m |
| Revenue (TTM) | CN¥307.69m |
126.8x
P/E Ratio5.5x
P/S RatioIs 688098 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688098 income statement (TTM) | |
|---|---|
| Revenue | CN¥307.69m |
| Cost of Revenue | CN¥99.67m |
| Gross Profit | CN¥208.02m |
| Other Expenses | CN¥194.58m |
| Earnings | CN¥13.44m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | 0.033 |
| Gross Margin | 67.61% |
| Net Profit Margin | 4.37% |
| Debt/Equity Ratio | 0% |
How did 688098 perform over the long term?
See historical performance and comparison